Safety and Tolerability of Sequential Pegylated IFN-α2a and Tenofovir for Hepatitis B Infection in HIV+ Individuals
Authors:
- 1 June 2007
- journal article
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 8 (3) , 173-181
Abstract
Chronic hepatitis B virus infections are a major cause of morbidity and mortality in HIV co-infected patients. The standard of care for treating HCV co-infection has been guided by major clinical trials, but the treatment of HBV co-infection has not been as thoroughly studied and the standard of care remains largely untested. The single pill formulation of tenofovir with emtricitabine has become a standard treatment approach in HBV co-infected patients. WU114 was a phase 1 clinical trial that examined the safety and tolerability of sequential treatment of HBV with pegylated interferon-α2a plus delayed-initiation tenofovir in HIV co-infected individuals. We postulated that initial HBV viral load reduction with pegylated interferon prior to initiation of nucleoside/nucleotide therapy would increase seroconversion events and durability of HBV virologic suppression. No severe pegylated IFN-α2a drug toxicities were seen in either the monotherapy or delayed tenofovir arms. Sequential pegylated interferon and tenofovir-based therapy was tolerable and should be compared with dual nucleoside/nucleotide suppression to determine relative frequencies of seroconversion and durability of HBV suppression in co-infected patients.Keywords
This publication has 40 references indexed in Scilit:
- Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfectionAIDS, 2006
- Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?AIDS, 2005
- Interferon-induced sarcoidosisInternational Journal Of Clinical Practice, 2005
- Alpha/Beta Interferon Differentially Modulates the Clearance of Cytoplasmic Encapsidated Replication Intermediates and Nuclear Covalently Closed Circular Hepatitis B Virus (HBV) DNA from the Livers of Hepatocyte Nuclear Factor 1α-Null HBV Transgenic MiceJournal of Virology, 2005
- Management of HBV/HIV-Coinfected PatientsSeminars in Liver Disease, 2005
- HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapyHIV Medicine, 2003
- Fidelity of hepatitis B virus polymeraseEuropean Journal of Biochemistry, 2003
- Durability of Serologic Response After Lamivudine Treatment of Chronic Hepatitis BHepatology, 2003
- An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individualsAIDS, 2003
- Interferon alfa treatment of chronic hepatitis B: Randomized trial in a predominantly homosexual male populationGastroenterology, 1995